Volume 13, Number 1—January 2007

Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha* , Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Figure 2

Figure 2. Human papillomavirus (HPV) prevalence by sex and age group, as predicted by the model and reported in selected studies from North America. HPV high risk includes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.